Practitioners

Healthcare Professionals

Do you have a refractory patient not responding to medication?

Imagine a safe and effective treatment for anxiety, insomnia, and pain

… all in one simple-to-use device
without the side effects of pain and psychiatric medication

Alpha-Stim is the most researched medical device in its class and the most widely used and recommended cranial electrotherapy stimulator in the world.

What is Alpha-Stim?

Alpha-Stim is a state-of-the art prescription medical technology for the treatment of anxiety,  insomnia and pain. Alpha-Stim utilizes a patented microcurrent waveform for unparalleled performance and safety.

Depending on the indication, a very mild electrical current is either applied with earclip electrodes to the head (a method called Cranial Electrotherapy Stimulation) or directly to the muscle and/or joint with hand-held probes or self-adhesive electrodes (a method called Microcurrent Electrical Therapy). Both treatments are well tolerated and safe.

The Alpha-Stim Advantage

  • Low incidence of adverse effects.
  • More efficacious than most other forms of therapy.
  • Relatively easy to learn.
  • Alternative in cases refractory to conventional care.
  • Reduces or eliminates need for addictive medications.
  • May be applied on schedule or PRN.
  • May be self-administered by patients.
  • Cumulative timer.
  • Stand-alone or adjunct therapy.

Alpha-Stim in Your Practice

Alpha-Stim is FDA-cleared to treat anxiety, insomnia and pain. Consequently, this unique technology can easily be incorporated into your practice, providing you with an effective treatment choice for your patients. Learn more how Alpha-Stim can complement your practice.

Alpha-Stim vs. Medication

Recent Publications

See a Complete list of Alpha-Stim Research

Results of the current [GAD] study demonstrate a significant improvement with CES, with a decrease in HARS score similar to that found in clinical trials with antidepressant and anxiolytic medications

Bystritsky et al. (2008). Journal of Clinical Psychiatry February 6, 2008: e1-e6- Developer

The large effect sizes for the effects of CES on anxiety and comorbid depression reveal a favorable risk/reward ratio supporting the use of CES for the treatment of anxiety and comorbid depression in evidence-based practice.

Barclay & Barclay (2014). Journal of Affective Disorders 164:171-177- Developer

The large effect sizes for the effects of CES on anxiety and comorbid depression reveal a favorable risk/reward ratio supporting the use of CES for the treatment of anxiety and comorbid depression in evidence-based practice.

Barclay & Barclay (2014). Journal of Affective Disorders 164:171-177- Developer